Key facts
- Chinese pharmaceutical companies are increasingly adopting AI for drug discovery.
- The focus is on AI-powered drug candidates to drive innovation.
- This trend is expected to lead to a new wave of mergers and acquisitions in the sector.
China's pharmaceutical industry is undergoing a significant transformation, with companies increasingly turning to artificial intelligence to discover and develop new drug candidates. This strategic shift is aimed at accelerating innovation and driving a new wave of mergers and acquisitions within the sector. By integrating AI into their research and development processes, Chinese drugmakers are seeking to enhance their competitive edge and unlock new opportunities for growth and collaboration. The focus on AI-powered candidates suggests a move towards more efficient and targeted drug development, which could reshape the landscape of pharmaceutical deals in the region.